Emerging paradigms and recent progress in targeting ErbB in cancers

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The epidermal growth factor receptor (EGFR) family, or ErbB receptors, are key targets in cancer therapy.
• Current treatments like tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) improve survival but face acquired resistance.
• Understanding ErbB signaling pathways is crucial for developing more effective anticancer strategies.

Purpose of the Study:

• To review recent advancements in targeting the ErbB receptor family.
• To elucidate emerging therapeutic paradigms for overcoming resistance to ErbB-targeted therapies.
• To highlight the potential of EGF domain-containing proteins (EDCPs) as novel therapeutic targets.

Main Methods:

• Literature review of recent advancements in ErbB-targeting strategies.
• Analysis of emerging insights into the ErbB family's cell surface interactome.
• Exploration of novel therapeutic approaches beyond traditional TKIs and mAbs.

Main Results:

• Recent progress includes inhibitory peptides, nanobodies, targeted-protein degradation, and bispecific antibodies (BsAbs).
• New avenues involve targeting specific domains of ErbB partners within the cell surface interactome.
• EGF domain-containing proteins (EDCPs) represent a promising new class of ErbB-targeting pathways.

Conclusions:

• Acquired resistance remains a significant challenge in ErbB-targeted cancer therapy.
• Novel strategies targeting ErbB signaling, including EDCPs, are essential for improving patient outcomes.
• Further research into the ErbB interactome will likely yield innovative therapeutic interventions.